1. Key messages
- Vaccines are one of the greatest successes in global health, having safely reduced the morbidity and mortality of different infectious diseases and saved at least 154 million lives worldwide over the past 50 years.
- In Belgium, as a result of vaccination, severe diseases like diphtheria or tetanus have become rare or even disappeared entirely (poliomyelitis, smallpox, congenital rubella).
- Even though circulation of most diseases has decreased, high vaccination coverage remains necessary and outbreaks can still occur due to immunity gaps in the population.
- Vaccination coverage for infants is high (>90%) throughout Belgium for all vaccines included in the free basic vaccination programs and is comparable between regions.
- Coverage declines after childhood: it is lower among adolescents, and even lower among adults in risk groups, with substantial regional disparities.
2. Epidemiology of some vaccine-preventable diseases
Success stories: no more polio and rubella in Belgium
Poliomyelitis is a highly infectious viral disease. It causes mild or no symptoms in most people, but in some people it can cause total paralysis or death. After the introduction of the polio vaccination in 1956, the incidence of polio sharply declined and cases have been rare following the introduction of mandatory vaccination in 1967. Since 2002, the European region has been considered polio-free by the World Health Organization (WHO). Currently, the risk of an epidemic in Belgium is low thanks to the high vaccination coverage.
Source: Sciensano, Epidemiology of infectious diseases [1]
Similarly, Belgium was certified by WHO as having eliminated rubella, thanks to vaccination. This virus can have severe consequences during pregnancy leading to stillbirth, congenital malformations and congenital rubella syndrome (CRS). The last autochthonous case of CRS in Belgium dates from 2007 and the last imported case from 2012. However, as long as these viruses are still circulating elsewhere, vaccination and surveillance remain necessary due to the risk of importation.
Disease outbreaks still occur due to immunisation gaps in the population
For most diseases targeted by vaccination, incidence has dropped drastically since the start of routine vaccination, but outbreaks still occur. Under-immunisation of certain groups or geographical regions significantly increases the risk of outbreaks. There was, for example, a diphtheria outbreak among asylum seekers in 2022, a group where vaccination remains difficult and coverage is too low [2].
In 2024, an important measles outbreak occurred, affecting mostly unvaccinated schoolchildren in Brussels. Also in 2025, case numbers remained elevated, this time mostly in Flanders due to an outbreak in a largely unvaccinated community in Antwerp. Both examples highlight the importance of high vaccination coverage throughout the entire population.
- Measles cases by region
- Measles cases by vaccination status
Number of reported measles cases per month in Belgium, by regions, 2015-2025
Source: Sciensano, Epidemiology of infectious diseases [1]
Number of reported measles cases in Belgium per age group, by vaccination status, 2025
Source: Sciensano, Epidemiology of infectious diseases [1]
Shifts in circulating serotypes of invasive infections slow down the success of vaccination campaigns
For invasive diseases like meningococcal and pneumococcal disease, current vaccines protect against certain serogroups/serotypes, but not all. Since the introduction of these vaccines in Belgium, circulation of strains included in the vaccine has dropped significantly. However, other strains not covered by the vaccine in the schedule are on the rise. This changing epidemiology does not indicate a failure of the vaccination policy, as total incidence remains lower than before vaccination programs were introduced. It does however highlight the need for development of new vaccines and adjustments in vaccination schedules. For example, the meningococcal vaccine was changed from MenC to MenACWY in 2023 to include three additional serogroups, after an increase in serogroups W and Y was observed. Also for pneumococcal disease, since 2025 the Superior Health Council recommends switching from PCV13 (which protects against 13 types of pneumococci) to PCV20 (which protects against 20 serotypes). This change would protect against 7 additional serotypes that are on the rise in Belgium, together responsible for half of all IPD cases in young children. Implementation of this recommendation is currently under consideration. For now PCV13 remains the vaccine provided in the free vaccination program.
- Meningococcal disease
- Pneumococcal disease
Number of cases of meningococcal disease, by serogroup, 2000-2025
Source: Sciensano, Epidemiology of infectious diseases [1]
Number of cases of invasive pneumococcal disease in children under 2, by serotypes included in different vaccines, 2019-2025
Source: Sciensano, Epidemiology of infectious diseases [1]
3. Vaccination coverage
3.1. Vaccination coverage for children under 2 years old
Vaccination coverage in Belgium is high and stable over time
In Belgium, the 90% coverage threshold set out in the WHO's Global Vaccine Action Plan (GVAP) [3] has been reached for full primary vaccination (1-4 doses depending on the vaccine) for all vaccines included in the recommended basic vaccination schedule, except for the rotavirus vaccine. The rotavirus vaccine is the only vaccine that is recommended for children but not provided in the free-of-charge vaccination program.
Source: Sciensano, Epidemiology of infectious diseases [4] and WHO [5], based on coverage surveys from Flanders in 2020 [6], Wallonia [7] and Brussels [8] in 2019
Vaccination coverage for vaccines in the basic vaccination programs is comparable for all Belgian regions
Vaccination coverage for vaccines in the basic vaccination programs for children is consistently high across all Belgian regions. National vaccination coverage for the full schedule (4 doses) of the hexavalent vaccine is 94%, with comparable coverage rates in all regions. The hexavalent vaccine is a vaccine that combines vaccination against six diseases in 1 shot (diphtheria-tetanus-pertussis (DTP), hepatitis B (HebB), Haemophilus Influenza type b (Hib), and poliomyelitis (polio)). Similarly, coverage for meningococcal (92%) and pneumococcal (94%) vaccines, as well as the first dose of measles-mumps-rubella (MMR1), show minimal regional differences.
Source: Sciensano, Epidemiology of infectious diseases [4], based on coverage surveys from Flanders in 2020 [6], Wallonia [7] and Brussels [8] in 2019
Rotavirus coverage is lower in Brussels and Wallonia
The rotavirus vaccine is recommended by the Superior Health Council (SHC) but is not included in the free vaccination programs by the regions. It is partially reimbursed by the RIZIV-INAMI, but parents still have to pay €7-12 per dose out of pocket. As a result, vaccination rates were lower than for the free vaccines in the basic vaccination program, especially in Brussels (69%) and Wallonia (80%). In Flanders, on the other hand, vaccination coverage was 92%. Recent analyses have further highlighted persistent inequalities in rotavirus vaccine uptake in Belgium, with lower vaccine uptake in socioeconomic vulnerable families and certain geographical areas. [9]
3.2. Vaccination coverage for adolescents
WHO targets for MMR and HPV vaccination coverage are not being met
The WHO targets of 95% for 2 documented doses of mumps, measles and rubella (MMR2) and ≥ 90% for human papillomavirus (HPV) coverage have not been reached in Belgium. Based on the latest available surveys, the weighted national average coverage for MMR2 has decreased from 82% to 73%, although it is unclear whether this represents a true decrease or rather an artefact due to limitations in the data*.
The national coverage for full HPV vaccination (2 doses) is 72% for girls, 65% for boys and 68% for girls and boys together. HPV vaccination has slowly been increasing over the years for girls. In 2019, vaccination for boys was introduced. Coverage in boys is currently lagging behind that of girls.
Source: Sciensano, Epidemiology of infectious diseases [4] and WHO [5], based on coverage surveys from Flanders in 2020 [6], and Fédération Wallonie-Bruxelles in 2024-2025 for MMR2 [10] and in 2022-2023 for HPV [11]
*Interpretation note
The reported MMR2 coverage should be interpreted as a lower limit. The apparent decrease may be explained by findings from the 2024–2025 vaccination coverage survey in the French-speaking community. Following the lowering of the recommended age for the second MMR dose from 11–12 years to 7–8 years, a smaller proportion of vaccinations were delivered through school health services, while more parents (18%) reported intending to vaccinate their child through their general practitioner. As current vaccination registries cannot verify the vaccination status of these children, they are not included in the reported number of vaccinated adolescents.
Important regional differences in coverage rates for adolescents
For adolescent vaccination, there are regional differences in both schedule and vaccination uptake. Following the advice from the Superior Health Council to lower the age for the second dose of MMR2, the French Community (FWB) and German-speaking Community lowered the age to 7-8 years old and the Flemish Community to 9-10 years old. In October 2025, Flanders lowered the age for MMR2 even further, to 24 months. In Flanders, the latest survey was performed in 2020, reporting coverage of 89%. FWB performed a new coverage survey in 2024-2025 that indicated a 52% coverage in the whole French Community and 59% for Brussels specifically*.
Also for HPV, the weighted national average hides important regional differences. In 2019-2020, Flanders had a full HPV vaccination coverage rate of 81% for both girls and boys, while the French Community had a coverage of 48%. In a new survey by FWB in 2022-2023, coverage in the French Community increased to 52%. Coverage in Brussels specifically increased from 39% to 41%.
Source: Sciensano, Epidemiology of infectious diseases [4], based on coverage surveys from Flanders in 2020 [6], and Fédération Wallonie-Bruxelles in 2024-2025 for MMR2 [10] and in 2022-2023 for HPV [11]
*The French community, or Fédération Wallonie-Bruxelles (FWB), includes Wallonia and the French-speaking part of Brussels Capital Region.
3.3. Vaccination coverage for adults
Vaccination is a lifelong intervention. While vaccination programs for infants and adolescents are well established, vaccination of adults remains more fragmented in Belgium. Consequently, vaccination coverage data are limited, but available evidence indicates that uptake of recommended vaccines among older adults, pregnant women and other risk groups remains suboptimal. For example, 51% of adults in risk groups eligible for influenza vaccination received an influenza vaccine in 2023, and only 14% of adults in risk groups had been vaccinated against pneumococcal disease [12]. Regional differences, already observed in adolescents, become even more pronounced in adulthood. For example, maternal pertussis vaccination coverage reached 85% in Flanders, compared with 39% in Wallonia and 31% in Brussels [4].
4. Read more
View the metadata for this indicator
Vaccine-preventable disease surveillance - Sciensano
Background
Childhood immunization in Belgium
The Belgian Superior Health Council decides, on a scientific basis, about the recommended vaccination schedule for children. This schedule currently includes vaccines for thirteen infectious diseases. Of these, the polio vaccine is the only one that is mandatory in Belgium. The different communities (Flemish, French and German-speaking Community) are then responsible for the implementation of the guidelines and practical organization of the vaccination campaigns. As a result, there are some regional differences in the age of administration of certain vaccines for children (see schedules for Flanders and Fédération Wallonie-Bruxelles) and in the vaccine brands that are being used. Extensive information can be found in the report “Vaccination policy and advice in Belgium” (available in Dutch and French).
In Belgium, vaccination coverage is monitored by coverage surveys organized and financed by the relevant regions/communities. These surveys take place approximately every four to five years. An estimate of national vaccination coverage in Belgium is calculated each year by Sciensano's Epidemiology of Infectious Diseases Department on the basis of the most recent vaccine coverage studies and weighted by population size. To study infant vaccination coverage, the same methodology is used in all three regions, with a sample drawn from the general population. The method used to study adolescent vaccination coverage differs from region to region. In Flanders, adolescent vaccination coverage studies are carried out on a general population sample. In Brussels and Wallonia, vaccination coverage surveys have been carried out every year on a sample of pupils in French-speaking schools [4]. In Flanders, an electronic vaccination registry, Vaccinet, has existed since 2006 and is being routinely used by all vaccinators. For the French community, new vaccination registries are currently being rolled out. In the future, registry-based vaccination coverage estimates might replace the periodical surveys.
Epidemiological reports
More detailed information on the epidemiology and surveillance of vaccine-preventable diseases can be found in the yearly reports on the specific health topic pages on Sciensano website:
- Poliomyelitis
- Diphtheria
- Whooping cough
- Haemophilus influenza type b
- Hepatitis B
- Measles
- Mumps
- Rubella
- Neisseria meningitides
- Streptococcus pneumoniae
- Rotavirus
- HPV
- Influenza
Definitions
- Immunization gaps
- Localized communities with low vaccine uptake (e.g., specific demographic groups, geographical areas, hard-to-reach communities, etc.), increasing their susceptibility to infection and the likelihood of outbreaks.
- Serotypes/serogroups
- Describes a way of grouping cells or microorganisms, such as bacteria, based on the antigens or other molecules found on their surfaces.
- Vaccine coverage
- Percentage of persons who received certain vaccine doses. For example, coverage of DTP3 is the percentage of infants who received all three doses of diphtheria, tetanus and pertussis (DTP) vaccine.
- Primary vaccination
- The initial series of vaccinations given to an individual to achieve immunity against a particular disease, usually involving multiple doses administered (1-4 depending on the vaccine) over a specified period to build a strong and long-lasting immune response.
References
- Sciensano. Epidemiology of vaccine-preventable infectious diseases. Annual summary report 2024. https://hdl.handle.net/20.500.14493/4167
- Jacquinet S, Martini H, Mangion J, Neusy S, Detollenaere A, Hammami N. Outbreak of Corynebacterium diphtheriae among asylum seekers in Belgium in 2022: operational challenges and lessons learnt. Eurosurveillance. 2023. https://doi.org/10.2807/1560-7917.ES.2023.28.44.2300130
- World Health Organization. Global vaccine action plan: monitoring, evaluation and accountability: secretariat annual report 2020. https://iris.who.int/handle/10665/337433
- Grammens T, Cornelissen L. Couverture vaccinale des vaccinations de base. 2022. https://hdl.handle.net/20.500.14493/3197
- WHO & Unicef. WHO/UNICEF Estimates of National Immunization Coverage (WUENIC). 2025. https://worldhealthorg.shinyapps.io/wuenic-trends/
- Maertens K, Willen L, Van Damme P, Roelants M, Guérin C, de Kroon M, et al. Studie van de vaccinatiegraad in Vlaanderen, 2020. https://www.laatjevaccineren.be/vaccinatiegraadstudie
- Robert E, Swennen B, Coppieters Y. Enquête de couverture vaccinale des enfants de 18 à 24 en Fédération Wallonie-Bruxelles (Bruxelles excepté), 2019. https://professionnels.vaccination-info.be/outils-ressources/enquete-de-couverture-vaccinale-18-24-mois-wallonie-2020/
- Robert E, Swennen B, Coppieters Y. Enquête de couverture vaccinale des enfants de 18 à 24 mois en Région de Bruxelles-Capitale, 2019. https://professionnels.vaccination-info.be/outils-ressources/enquete-de-couverture-vaccinale-18-24-mois-bruxelles-2020/
- Dambre C, Rousseau R, Hansford K, Cornelissen L. Analyse du taux de vaccination et des déterminants socio-économiques sur la base des données de remboursement de l’AIM. 2026. https://hdl.handle.net/20.500.14493/5861
- Oulare M, Sarr K, Brasseur C, Carrillo-Santisteve P. Résumé enquête de couverture vaccinale 2024-2025. La vaccination contre la rougeole, la rubéole et les oreillons (RRO) chez les élèves de 2ème primaire dans l’enseignement de la Fédération Wallonie-Bruxelles. https://professionnels.vaccination-info.be/outils-ressources/enquete-de-couverture-vaccinale-rro-2024-2025/
- Brasseur C, Sarr K. Résumé enquête de couverture vaccinale 2022-2023. La vaccination contre le papillomavirus humain (HPV) chez les élèves de 2ème secondaire dans l’enseignement de la Fédération Wallonie-Bruxelles. https://www.ccref.org/e-vax/pdf/ECV_2022-2023_HPV_Resume.pdf
- Sciensano. Health Interview Survey 2023-2024. https://healthinformation.sciensano.be/shiny/hisia/
Please cite this page as: Sciensano. Communicable Diseases: Vaccine-preventable diseases, Health Status Report, 23 July 2026, Brussels, Belgium, https://www.healthybelgium.be/en/health-status/communicable-diseases/vaccine preventable diseases